Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer

Inclusion Criteria: * Either bronchioloalveolar cell carcinoma or a variant thereof after review * Clinical stage IIIB (malignant pleural or pericardial effusion) or IV or recurrent/medically inoperable disease * Measurable or evaluable indicator lesions * No prior or one chemotherapy regimen for NSCLC * Three weeks since last chemotherapy, and three weeks since prior radiation therapy to a major bone-marrow containing area * Karnofsky performance status \> or = to 80% OR ECOG performance status ≤ or = to 1 * Life expectancy \> or = to 8 weeks * Adequate hematologic, renal and/or hepatic function: WBC \> or = to 3,000/ul, hemoglobin \> or = to 9.0 g/dl, platelet count \> or = to 100,000/ul, total bilirubin \< or = to 1.0 mg/dl, AST \< than or = to 2.5 X UNL, creatinine \< or = to 1.5 mg/dl or Clcr \> or = to 55ml/min. * Effective contraception Exclusion Criteria: * Prior exposure to OSI-774 or other treatments targeting the HER family axis (e.g.-trastuzumab, ZD1839, C225, etc.) * Two or more prior chemotherapy regimens * Concurrent active cancer * Uncontrolled central nervous system metastases (i.e. any known CNS lesion which is radiographically unstable, symptomatic and/or requiring escalating doses of corticosteroids) * Pregnant or lactating women * Malignancies within the past 5 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin * Prior systemic cytotoxic chemotherapy for other malignant disease * Significant medical history or unstable medical condition (unstable systemic disease: congestive heart failure, recent MI, unstable angina, active infection, uncontrolled hypertension).